The United Kingdom and the United States have agreed to a key trade agreement that will preserve zero duties on British medicine shipments being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to boost spending on medicines through the National Health Service (NHS). This pledge ensures that import taxes on these crucial exports will stay at zero for a duration of 36 months.
This deal follows earlier threats to hike tariffs on patented drug imports, with figures floated as high as 100%.
"This agreement between the UK bolsters the international landscape for innovative medicines and brings long-overdue balance to transatlantic pharmaceutical trade," a release said.
Trade Importance
Medicines constitute one of the Britain's largest goods shipped to the US, which is clearly the biggest buyer for large companies like GSK and AstraZeneca.
Export figures indicate that in the year leading up to September, the UK shipped medicines totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards work, stimulates capital expenditure and sets the stage for the UK to become a worldwide center for life sciences," a minister stated.
Detailed British Pledges
The deal involves several notable commitments from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase total public funding on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The sum drug companies must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, rebates topped 20%.
Broader Context
This agreement follows a ongoing dispute between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
These tensions were heightened by claims that American customers were charged significantly more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the last ten years.
